Mark J. Ratain to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications Mark J. Ratain has written about Antineoplastic Agents, Hormonal.
Connection Strength
0.410
-
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
Score: 0.119
-
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
Score: 0.101
-
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec; 70(6):854-69.
Score: 0.090
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
Score: 0.037
-
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy. J Clin Oncol. 2016 11 10; 34(32):3944-3945.
Score: 0.034
-
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
Score: 0.015
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.014